BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines vIDAZA (azacitidine — BMS/Celgene China Partnered) ($M, FY18–FY23) ($M)
Form 10-Q / 10-K Segment Disaggregation Note (XBRL)
Latest, FY2023
14
Period ended Dec 31, 2023
Change on a year earlier
-7.9%
15.2 in FY2022
History
6 years
Since FY2018
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | VIDAZA (azacitidine — BMS/Celgene China Partnered) ($M, FY18–FY23) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 14 | -7.9% | Form 10-K (filed 2024-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 15.2 | -22.4% | Form 10-K (filed 2024-02-26) ↗ |
| FY2021 | Dec 31, 2021 | 19.6 | -34.7% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 30 | -6.8% | Form 10-K (filed 2023-02-27) ↗ |
| FY2019 | Dec 31, 2019 | 32.2 | +666.7% | Form 10-K (filed 2022-02-28) ↗ |
| FY2018 | Dec 31, 2018 | 4.20 | – | Form 10-K (filed 2021-02-25) ↗ |
Cite this data
StockData. (2026). BeOne Medicines VIDAZA (azacitidine — BMS/Celgene China Partnered) ($M, FY18–FY23) ($M), annual FY2018–FY2023 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod_vidaza
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.